Log in
NASDAQ:ALXO

ALX Oncology Stock Forecast, Price & News

$38.26
-1.52 (-3.82 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$37.78
Now: $38.26
$42.34
50-Day Range
$37.08
MA: $41.71
$47.10
52-Week Range
$28.01
Now: $38.26
$52.00
Volume83,082 shs
Average Volume153,109 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for ALX Oncology Holdings Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALXO
CUSIPN/A
CIKN/A
Phone650-466-7125

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$1.41 billion
Next Earnings Date11/26/2020 (Estimated)
OptionableNot Optionable
$38.26
-1.52 (-3.82 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALXO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ALX Oncology (NASDAQ:ALXO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of ALX Oncology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ALX Oncology
.

When is ALX Oncology's next earnings date?

ALX Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 26th 2020.
View our earnings forecast for ALX Oncology
.

Who are some of ALX Oncology's key competitors?

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV), Axon Enterprise (AAXN), Atlas Air Worldwide (AAWW) and Anglo Australian Resources (AAR).

When did ALX Oncology IPO?

(ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is ALX Oncology's stock symbol?

ALX Oncology trades on the NASDAQ under the ticker symbol "ALXO."

When did ALX Oncology's quiet period expire?

ALX Oncology's quiet period expired on Wednesday, August 26th. ALX Oncology had issued 8,500,000 shares in its IPO on July 17th. The total size of the offering was $161,500,000 based on an initial share price of $19.00. During ALX Oncology's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of ALX Oncology?

Shares of ALXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ALX Oncology's stock price today?

One share of ALXO stock can currently be purchased for approximately $38.26.

How big of a company is ALX Oncology?

ALX Oncology has a market capitalization of $1.41 billion.

What is ALX Oncology's official website?

The official website for ALX Oncology is www.alxoncology.com.

How can I contact ALX Oncology?

ALX Oncology's mailing address is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. The company can be reached via phone at 650-466-7125 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.